MARKET

FENC

FENC

Fennec Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.22
+0.13
+1.61%
Closed 16:00 07/02 EDT
OPEN
8.03
PREV CLOSE
8.09
HIGH
8.30
LOW
7.87
VOLUME
230.59K
TURNOVER
--
52 WEEK HIGH
9.75
52 WEEK LOW
3.750
MARKET CAP
208.43M
P/E (TTM)
-11.7027
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FENC stock price target is 18.00 with a high estimate of 21.00 and a low estimate of 15.00.

EPS

FENC News

More
Fennec Pharmaceuticals amends its debt facility
Seeking Alpha - Article · 06/26 16:23
Fennec Pharmaceuticals boosts size of debt facility
Seeking Alpha - Article · 06/26 16:23
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
GlobeNewswire · 06/26 11:00
Fennec Pharma Raises Size Of Existing Senior Debt Facility From $12.5M To $18M
Benzinga · 06/26 10:05
3 Perfect 10 Stocks Under $10 With Big Upside Potential
TipRanks · 06/23 15:50
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 22, 2020 -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management.
GlobeNewswire · 06/22 22:04
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About FENC

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
More

Webull offers kinds of Fennec Pharmaceuticals Inc stock information, including NASDAQ:FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.